SVU - International Journal of Medical Sciences (Jan 2024)

Seroprevalence of Toxoplasma Gondii among Cancer patient in Qena Governate

  • Osama Hussein Abd Ellah ,
  • Asmaa Hamdy Mobarak*,
  • Mohamed Mostafa Ali Wahman,
  • Eman Abd El Azeem ,
  • Asmaa M Elkady

DOI
https://doi.org/10.21608/svuijm.2021.64617.1096
Journal volume & issue
Vol. 7, no. 1
pp. 245 – 250

Abstract

Read online

Background: Toxoplasmosis is one of the most important cosmopolitan life-threatening diseases in immune-compromised patients. It is caused by an intracellular protozoon: Toxoplasma gondii (T. gondii), this parasite can cause pneumonia, encephalitis or disseminated disease in immune-deficient patients. Objectives: This study aimed to evaluate the prevalence of toxoplasmosis in Egyptian cancer patients and to correlate the prevalence with type of malignancy and the different cancer treatment modalities. Patients and Methods: This study conducted on 100 cancer patients (21 male and 79 female) who attended the Oncology Outpatient Clinic of Qena University Hospital and diagnosed by cancer , receiving chemotherapy or both chemotherapy and radiotherapy, and their ages ranging from 20 year to 76 years from January 2019 until December2020. Results: The high incidence of Toxoplasmosis was among cancer breast patient. The mean of Ig M titre is 0.849 with minimum level is 0.15 and maximum level is 10.43. There were 70 cancer patients undergoing chemotherapy, 6 of them were positive for toxoplasma Ig M (8.7%) , but 30 of whom received chemotherapy and radiotherapy, 11 of whom were infected (36.7%) according to the IgM level. Conclusion: Patients with a positive result are at risk of reactivation of the infection, while patients with a negative result should be informed to prevent primary infection.

Keywords